Articles tagged with Tumor Cells
Researchers have uncovered a weakness in the key enzyme that solid tumour cancer cells rely on to adapt and survive when oxygen levels are low. Inhibiting this enzyme, called Carbonic Anhydrase IX (CAIX), can effectively stop cancer cell growth.
Researchers at the University of Southampton have identified a unique change in B cells that allows them to receive signals from molecules called lectins, enabling tumor growth. This discovery could pave the way for new treatments and early cancer detection methods.
Researchers discovered that noncoding RNA derived from pericentromeric repetitive sequences upregulates SASP-like inflammatory gene expression by disturbing chromatin interactions. hSATII RNA is highly detectable in cancer cells and supports tumor development via small EVs, highlighting a new role in age-related pathologies.
A study by the Center for Cell-Based Therapy in São Paulo, Brazil, has discovered a set of biomarkers that can be used to predict which patients with glioblastoma may have tumors resistant to radiation therapy. The genetic signature helps doctors choose the best treatment option for these patients.
Researchers have developed heat-controllable CAR T cells that can target and destroy cancerous tumors, while preventing relapse. The cells are engineered to produce immunomodulators under photothermal control, increasing their effectiveness against solid tumors.
Researchers uncover how cancer cells make lactic acid to thrive in low-oxygen environments, a process enabled by the PRL-3 protein. This discovery holds promise for developing inhibitors to disrupt this survival mechanism.
Researchers have discovered how PARP inhibitors selectively kill cancer cells carrying BRCA1 and BRCA2 mutations. The findings provide a mechanistic explanation for the selectivity of PARP inhibitors toward BRCA-mutant cells.
Researchers found that microscopic defects in healthy cell alignment can slow down tumor cell invasion. The study used an experimental model to show how topological defects affect the rate of tumor cell invasion, with certain defects causing cancer cells to pass through the barrier more slowly.
Researchers have found a way to harness the power of immunotherapy for advanced prostate cancer by targeting a protein called PIKfyve. Blocking PIKfyve with the inhibitor ESK981 has been shown to increase tumor death and recruit immune T cells, offering new hope for patients with this challenging form of cancer.
Scientists have discovered a way to restrict the activity of Tregs, which regulate the immune system and prevent it from attacking healthy cells. Inhibition of PIP4K enzymes in Tregs allows Teff cells to function more effectively, leading to better cancer treatment outcomes.
Researchers developed a 3D platform to study therapeutic combinations against cancer cells, allowing for rapid optimization of personalized immunotherapies. The platform demonstrated significant differences in treatment efficacy between 2D cell cultures and the 3D spheroid design.
Researchers have discovered that increased levels of protein Tumour Protein D54 can increase and decrease the movement of cancer cells, suggesting its potential role in tumour spread. The study found that reducing or increasing this protein's expression affects cell migration, with higher levels leading to more metastasis.
Luay Nakhleh's team will use single-cell DNA data from the University of Texas MD Anderson Cancer Center to identify mutations at the root of the disease and how they evolve in tumors. By building open-source models and tools, they aim to refine cancer treatments and predict patient outcomes.
Researchers have discovered that a small percentage of drug-resistant cancer cells were already present before treatment, relying on alternative genes for survival. Understanding this mechanism is key to developing new treatments to eliminate both AXL- and EGFR-dependent cells from the start.
Researchers identified a specialized protein called TRPM7 that regulates the key step in cancer metastasis by sensing fluid flow and stopping cells from entering the bloodstream. Artificially increasing TRPM7 expression in tumor cells may help stop intravasation and ultimately metastasis.
Researchers discovered that colorectal cancer cells exploit an innate immune system activator to fuel their own growth and eliminate surrounding healthy cells. This feedback loop disrupts the balance of cell growth and differentiation, allowing tumors to expand and spread.
A phase 3 trial found that Lu-PSMA-617 significantly improved survival and progression-free survival of patients with metastatic castration-resistant prostate cancer. The treatment delivered beta radiation directly to tumour cells, keeping them alive for longer than standard care.
Scientists have found that short-chain fatty acids can increase the efficiency of tumor therapies by boosting the activity of killer cells. The researchers identified pentanoate, produced by Megasphaera massiliensis bacteria, as a key player in this process.
Researchers have devised a way to multiply the accessible details of gene activity in individual cells, allowing for better understanding of cancer development and brain function. The new method delivers about a ten-fold improvement in DNA recovery from single cells and reduces sequencing costs by one third.
Researchers from UNIGE and Harvard Medical School have discovered the difference between desired immune responses targeting cancer cells and unwanted responses affecting healthy tissue. By understanding these differences, they aim to develop new therapeutic approaches that minimize toxic side effects and maximize treatment efficacy.
Researchers used machine learning to analyze tumor microenvironment and identify biomarkers that predict patient response to immunotherapy. The model outperformed current biomarkers, enabling personalized treatment and better understanding of biological mechanisms involved.
Researchers discovered hematopoietic stem cells in glioblastomas, which promote division of cancer cells and suppress the immune response. These blood stem cells stimulate tumor growth and produce immunosuppressive messengers.
Researchers found 556 novel markers of colorectal tumors with microsatellite instability, which are differentially expressed genes. These markers were identified by incorporating cell composition into their regression model, indicating a potential role in disease prognosis.
Researchers at McMaster University have developed a promising new cancer immunotherapy that uses genetically engineered natural killer cells to find and destroy malignant tumors. The modified cells can differentiate between cancer cells and healthy cells, bringing new promise to this branch of immunotherapy.
ASU engineering researchers have discovered a new neural stem cell state that could be key to unlocking new methods of brain cancer treatment. The team found that the quiescent Neural G0 state is independent of a tumor's proliferation rate and can potentially be targeted for new drug treatments.
Scientists at Princess Máxima Center developed a new imaging technique to study millions of cells in 3D tissue, revealing hundreds of features from each individual cell. The technique helps analyze molecular profiles and cell shape, potentially improving diagnosis and treatment for children's cancers.
New research suggests that treating cancer patients with anti-CTLA4 therapies before anti-PD1 treatment can improve overall survival. High numbers of T follicular regulatory (Tfr) cells in tumors may be to blame for the lack of response to anti-PD1 therapies.
The study found ADCs made with cleavable linkers can decrease small-cell lung cancer tumor size in PDX mouse models, showing promise for improved efficacy. The 'bystander effect' kills nearby nontargeted cancer cells often found near malignant tumors.
A recent UCI-led study reveals that cancer immunotherapy can trigger both favorable and unfavorable immune effects, with T regulatory cells playing a key role in limiting tumor control. The study found that CTLA-4 blockage activates these cells, decreasing the efficacy of immunotherapy and potentially leading to fatal autoimmunity.
A recent study found that a small percentage of cells in aggressive tumors can enable metastasis by recruiting surrounding cells. This discovery could lead to new approaches in preventing malignant progression of breast cancer, particularly in triple-negative types.
Researchers found that PrimPol helps cells survive chemotherapy damage by facilitating DNA repair; repressing this protein could make tumor cells more sensitive to cancer treatments. This discovery has implications for Fanconi anaemia, a rare disease with few therapeutic options.
Scientists at Rockefeller University have identified a new class of therapeutics that destroy fibrolamellar tumor cells growing in mice. The team tested over 5,000 compounds to find these effective treatments, which could potentially transform the landscape of precision medicine by tailoring treatment options for individual patients
Researchers at Université catholique de Louvain discovered that DHA slows the development of tumors by poisoning cancer cells through a phenomenon called ferroptosis. This mechanism is triggered when acidotic tumor cells absorb excessive amounts of unsaturated fatty acids, leading to cell death.
A study evaluating 22 patients with recurrent Anti-hormonal granulosa cell tumors found low-to-moderate FDG uptake and variable ERα/ERβ expression. FES-PET/CT showed promising results in identifying treatment-eligible patients, with stable tumor locations decreasing in size during anti-hormonal treatment.
Researchers have identified specific cell types and tumor pathways that can predict which kidney cancers respond to immunotherapy, offering new insights into treatment strategies. The study's findings could lead to the development of biomarkers to guide kidney cancer treatment.
Researchers discovered that metabolites from fungi and bacteria biofilms can modulate gene expression associated with tumor growth and survival. The study found that these microorganisms can endanger homeostasis in normal and neoplastic oral epithelial cells, impairing cell viability and survival.
A new single-cell analysis tool identifies a unique sub-population of macrophages in kidney tumors associated with disease recurrence. The tool, called meta-VIPER, builds on previous techniques to accurately detect gene activity in individual cells, revealing potential targets for treatment and improving clinical outcomes.
Researchers at NYU Abu Dhabi have developed a non-contact probe that enables the analysis of single cells within tumors without disrupting their spatial configurations. The tool can also introduce foreign materials to selected cells, facilitating advanced studies on complex diseases like cancer and Alzheimer's.
A multidisciplinary study has found that cells at the centre of kidney tumours have a higher potential to spread to secondary sites around the body. By contrast, cells at the tumour edge had lower rates of metastasis and growth.
Researchers find a way to target both pancreatic cancer cells and the scar tissue surrounding them, reducing tumor growth and spreading. A new clinical trial aims to test this approach with an existing anti-arthritis drug, potentially improving treatment response and patient survival.
Biomedical engineer Chase Cornelison is exploring ways to harness cancer cells to treat spinal cord injuries and restore function following brain damage. His research aims to retrain neural cells to suppress inflammation and promote repair, potentially reversing the damage caused by paralysis and diseases.
Researchers discovered that deleting the aryl hydrocarbon receptor from oral cancer cells results in a robust tumor-specific immune response, allowing mice to reject the cancer. This finding provides a new target for cancer immunotherapy treatment, potentially leading to more effective treatments.
Scientists from UNIGE and UZH used a statistical physics approach to study wound healing, identifying the scales of dominant cell interactions that govern tissue growth. The results allow for better analysis of cell front behavior in both healthy tissue and tumour development.
A new strategy combines AIEgen-mediated photodynamic therapy with Poly(I:C)-based immunotherapy to enhance anti-tumor immune responses. The system induces tumor cell death and stimulates cytokine release, demonstrating potential for preventing tumor recurrence and metastasis.
Researchers at UCSF have engineered smart immune cells effective against solid tumors, overcoming hurdles for immunotherapies. The new approach may be ready for clinical trials in the near future, offering hope for patients with previously untouchable cancers.
A new method called XYZeq allows researchers to map variation across cells in a tissue or tumor, gaining insight into their spatial location and function. The technique enables the analysis of cellular patterns in complex environments like cancerous tumors and other organs.
A recent study by Vanderbilt researchers reveals that non-cancer cells in a tumor, primarily immune cells called macrophages, have the highest glucose uptake, upending traditional models of cancer metabolism. This finding could lead to new therapies and imaging strategies.
Researchers discovered two subsets of tumor cells that can be targeted using different methods, one inducing ferroptosis and the other inhibiting antioxidant production. The study found that combining these approaches could improve treatment outcomes for small cell lung cancer patients.
Researchers discovered a cell-to-cell communication network that instructs tumor cells in tissues to regrow after genotoxic therapy. The study found that elevated p53 levels and release of interleukin-6 signal cells to activate growth signals, leading to tumor regrowth.
Researchers found that autophagy selectively degrades PKA inhibitory subunit RIa, promoting mitochondrial metabolism and tumor cell growth. Suppression of AKAP11 levels in tumor cells prevents degradation and blocks PKA activation, inhibiting tumor cell growth.
Scientists have identified new biomarkers in exosomes produced by cancer stem cells, which could help diagnose and predict malignant melanoma. These biomarkers were found to be present in the blood of patients with different stages of the disease, distinguishing them from healthy individuals.
Researchers have identified a key protein, DAPK3, that plays a crucial role in the body's early immune response to cancer. The discovery highlights a new approach to cancer immunotherapy, where targeting the tumor's own innate immune system can help slow tumor growth and improve treatment outcomes.
Researchers at the University of Chicago developed a new therapeutic vaccine that uses a patient's own tumor cells to train their immune system to find and kill cancer. The vaccine stopped melanoma tumor growth in mouse models and promoted a broad, robust immune response, preventing new tumor growth when tumor cells were re-introduced.
Researchers developed a new vaccine that uses a patient's own tumor cells to train the immune system to find and kill cancer, promoting a broad and robust immune response. The therapy has shown long-term efficacy against metastasis and relapse in mouse models, offering potential for treatment of various cancers.
Researchers have identified YAP as a key regulator in the development and spread of basal-like breast cancer. Inhibiting YAP activity with medication can significantly reduce tumour volume, offering new hope for patients' survival.
Researchers at Imperial College London have developed a new type of nanoprobe that uses second harmonic generation (SHG) to detect tumors more brightly and precisely than existing fluorescent nanoprobes. The biodegradable bioharmonophores attach specifically to tumor cells, reducing misrepresentation and improving detection sensitivity.
Researchers discovered that metastatic cancer cells use adhesion and contractility to move away from stiffer tissue, defying the typical durotaxis process. By modulating cell contractility, they can change their ability to migrate in response to environmental stiffness.
Researchers have developed a lower-dose radiopharmaceutical that improves treatment efficacy for neuroendocrine cancers while reducing side effects. The new medication uses reversible binding technology to extend its half-life in the blood, providing an extended therapeutic time window and improved treatment outcomes.
Researchers assessed tumor cell isolation and in vitro proliferation assays to predict chemotherapy response in ovarian cancer. In 12 of 14 cases, in vitro drug sensitivity correlated with clinical outcome.
Researchers successfully developed bispecific antibodies that can target and deplete cancer cells without damaging healthy ones, including mutant tumor suppressor genes like p53. These antibodies could be used 'off-the-shelf' and are a promising alternative to engineered immune cell therapies.